GSK expedites Blenrep timelines as it eyes second chance in multiple myeloma

GSK wants to present Blenrep to regulatory bodies sooner.

The UK pharma will submit Blenrep in second-line multiple myeloma to US, European and Japanese authorities in the second half of 2024, which is earlier than the original 2025 guidance, according to its first-quarter earnings report. The filings will be based on positive outcomes from the Phase 3 DREAMM-7 and DREAMM-8 studies reported earlier this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

New drug strategy reverses resistance to immunotherapy in pancreatic cancer

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a susceptible one, according to a study

November 15, 2024

Researchers identify new biomarker to predict neuronal regeneration after injury

Neurons, the main cells that make up our brain and spinal cord, are among the slowest cells to regenerate after an injury, and many neurons

October 16, 2023

Vegetables, legumes, and seafood diet linked to lower heart risk in older men

Study reveals that a diet rich in vegetables, legumes, and seafood significantly reduces the risk of major adverse cardiovascular events in men over 75, compared

January 4, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.